Vivek Subbiah: Fantastic keynote lecture on “The FDA perspective on early phase pre-market dose optimization” by the amazing Dr. Paul Kluetz.

Vivek Subbiah shared on X/Twitter:

“Fantastic keynote lecture on “The FDA perspective on early phase pre-market dose optimization” by the amazing Dr. Paul Kluetz.

• OCE’s Project Optimus
• Dose optimization in early phase drug development
• Patient reported outcomes and patient generated data
• Master Protocols
• Decentralized elements

Wow! Every slide and every bullet point resonates with early phase investigators. Standing ovation.”

Source: Vivek Subbiah/Twitter

Vivek Subbiah is the Chief of Early-Phase Drug Development at the  Sarah Cannon Research Institute. He is the former Executive Director of Oncology Research at the MD Anderson Cancer Network and a former Associate Professor in the Department of Investigational Cancer Therapeutics at The University of Texas MD Anderson Cancer Center. Dr. Subbiah’s research interests include drug development in rare cancers, immunotherapy, and radiopharmaceuticals.